Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002286 · ClinicalTrials.gov registry record · NA
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
A NA study of HIV Infections and Psoriasis, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002286: Completed NA study of HIV Infections and Psoriasis, sponsored by Glaxo Wellcome.
NCT00002286 is a NA study of HIV Infections and Psoriasis that has completed, run by Glaxo Wellcome. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002286, a NA study of HIV Infections and Psoriasis, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
Conditions Studied
Interventions
- DRUG Zidovudine
Study Locations (1)
North Carolina
- Glaxo Wellcome Inc - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002286 record still lists
NCT00002286 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.
NCT00002286 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00002286 about?
NCT00002286 is a clinical study titled "A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients". To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT'...
What is the current status of trial NCT00002286?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002286 study?
This clinical trial studies the following conditions: HIV Infections, Psoriasis.
What interventions are being tested in trial NCT00002286?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002286?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002286 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA